Book Value per Share: BioAge Labs, Inc. (BIOA)

Graphic logo of BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. (BIOA) leverages artificial intelligence and computational genome analysis to combat metabolic pathologies. This daily price chart on the GURU.Markets platform captured a value of 8.19. Robotic compound synthesis accelerates the search for anti-aging treatments, although final tests require medical supervision. Meanwhile, the company's strategy relies on a narrow pipeline of developments, creating binary risks characteristic of startups.

BioAge Labs (BIOA): Share Book Value from 09/27/2024 to 10/27/2026

bioagelabs.com - analytical breakdowns and key metrics (BIOA)

- price and consensus price forecast:
Price Chart BioAge Labs Inc.|BIOA - Average Forecast Price
- market capitalization data:
Market Capitalization BioAge|BIOA - Enterprise Value
- book capitalization data:
Net Assets per Single Share BioAge Labs, Inc.|BIOA - Net Asset Value|Market Capitalization to Book Value Ratio bioagelabs.com|BIOA - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital BioAge Labs, Inc.|BIOA - Long-Term Debt to Capital|Short-Term Debt to Equity BioAge|BIOA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio BioAge
Fundamental company valuation:BioAge Labs Inc. - BIOA
Manufactured products of BioAge

The price action of the current book value per share reflects the capitalization rate of BioAge Labs, Inc. (BIOA) amid the development of drugs via its AI platform. This indicator is calculated as the ratio of equity minus intangible assets to the number of shares outstanding, demonstrating the real value of an investor's stake in the business. The steady growth of this metric confirms the company's resilience to stringent FDA oversight and minimizes the risk of capital loss.

Competitors of BioAge Labs, Inc. (BIOA)

ASND (Ascendis Pharma Inc.) - Net Assets per Single Share|MDGL - Net Asset Value per Share|CORT: Book Value per Share|RYTM (rhythmtx.com) - Book Value per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS